[
  {
    "ts": null,
    "headline": "BioNTech's Deal With Bristol Myers Over BNT-327 May Be Overhyped",
    "summary": "BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with Bristol-Myers and its impact on the firm.",
    "url": "https://finnhub.io/api/news?id=3b4d267b84e590d244dbc91899c713ddce2466b9e38166ef71a801e3885602a7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749032463,
      "headline": "BioNTech's Deal With Bristol Myers Over BNT-327 May Be Overhyped",
      "id": 135009841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403976499/image_1403976499.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with Bristol-Myers and its impact on the firm.",
      "url": "https://finnhub.io/api/news?id=3b4d267b84e590d244dbc91899c713ddce2466b9e38166ef71a801e3885602a7"
    }
  }
]